Unknown

Dataset Information

0

Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).


ABSTRACT: Second-generation COVID-19 vaccines with improved immunogenicity (e.g., breadth, duration) and availability (e.g., lower costs, refrigerator stable) are needed to enhance global coverage. In this work, we formulated a clinical-stage SARS-CoV-2 receptor-binding domain (RBD) virus-like particle (VLP) vaccine candidate (IVX-411) with widely available adjuvants. Specifically, we assessed the in vitro storage stability and in vivo mouse immunogenicity of IVX-411 formulated with aluminum-salt adjuvants (Alhydrogel™, AH and Adjuphos™, AP), without or with the TLR-9 agonist CpG-1018™ (CpG), and compared these profiles to IVX-411 adjuvanted with an oil-in-water nano-emulsion (AddaVax™, AV). Although IVX-411 bound both AH and AP, lower binding strength of antigen to AP was observed by Langmuir binding isotherms. Interestingly, AH- and AP-adsorbed IVX-411 had similar storage stability profiles as measured by antigen-binding assays (competitive ELISAs), but the latter displayed higher pseudovirus neutralizing titers (pNT) in mice, at levels comparable to titers elicited by AV-adjuvanted IVX-411. CpG addition to alum (AP or AH) resulted in a marginal trend of improved pNTs in stressed samples only, yet did not impact the storage stability profiles of IVX-411. In contrast, previous work with AH-formulations of a monomeric RBD antigen showed greatly improved immunogenicity and decreased stability upon CpG addition to alum. At elevated temperatures (25, 37°C), IVX-411 formulated with AH or AP displayed decreased in vitro stability compared to AV-formulated IVX-411and this rank-ordering correlated with in vivo performance (mouse pNT values). This case study highlights the importance of characterizing antigen-adjuvant interactions to develop low cost, aluminum-salt adjuvanted recombinant subunit vaccine candidates.

SUBMITTER: Kumru OS 

PROVIDER: S-EPMC10760504 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).

Kumru Ozan S OS   Bajoria Sakshi S   Kaur Kawaljit K   Hickey John M JM   Van Slyke Greta G   Doering Jennifer J   Berman Katherine K   Richardson Charles C   Lien Hans H   Kleanthous Harry H   Mantis Nicholas J NJ   Joshi Sangeeta B SB   Volkin David B DB  

Human vaccines & immunotherapeutics 20230801 2


Second-generation COVID-19 vaccines with improved immunogenicity (e.g., breadth, duration) and availability (e.g., lower costs, refrigerator stable) are needed to enhance global coverage. In this work, we formulated a clinical-stage SARS-CoV-2 receptor-binding domain (RBD) virus-like particle (VLP) vaccine candidate (IVX-411) with widely available adjuvants. Specifically, we assessed the <i>in vitro</i> storage stability and <i>in vivo</i> mouse immunogenicity of IVX-411 formulated with aluminum  ...[more]

Similar Datasets

| S-EPMC9621007 | biostudies-literature
| S-EPMC10303432 | biostudies-literature
| S-EPMC11796538 | biostudies-literature
| S-EPMC3485880 | biostudies-literature
| S-EPMC6530223 | biostudies-literature
| S-EPMC5220009 | biostudies-literature
| S-EPMC6089638 | biostudies-literature
| S-EPMC4494345 | biostudies-literature
| S-EPMC10923862 | biostudies-literature
| S-EPMC7915698 | biostudies-literature